The standard option for many patients with non-small cell lung cancer today is AstraZeneca’s targeted therapy Tagrisso. A year and a half ago, data showed this drug could provide patients with ...

Johnson & Johnson's Janssen division has claimed a first approval in the US for its bispecific antibody Rybrevant as a treatment for EGFR-mutated non-small cell lung cancer (NSCLC).

Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received a positive opinion from the ...

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

Johnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe, chasing after a rival therapy from Bristol-Myers Squibb.

Janssen-Cilag International NV, a Johnson & Johnson company, received European Medicines Agency's Committee for Medicinal Products ...

A better understanding of early childhood microbiome shifts offers a unique window for detecting disease risk and intervening appropriately. Experts from the Women’s Brain Foundation and bit.bio will ...

Janssen looks for partnerships where the sum is greater than the parts—a synergistic focus that benefits both parties. As part of Johnson & Johnson, Janssen can leverage an array of resources to ...

Johnson & Johnson’s shot is given in one dose, and through mid-August was shown to be 71% effective against hospitalization. Yes. The CDC in August recommended that all pregnant people get ...